Mitobridge Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 26

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $225M

Mitobridge General Information

Description

Developer of small molecule therapeutics designed to enhance mitochondrial function. The company's small molecule therapeutics help to improve mitochondria function and provide treatment for genetic, metabolic, and neurodegenerative disorders, as well as diseases and conditions of aging, enabling patients to begin treatment more quickly and resulting in a higher likelihood of successful treatment.

Contact Information

Website
www.mitobridge.com
Formerly Known As
Mitokyne
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 1030 Massachusetts Avenue
  • Suite 200
  • Cambridge, MA 02138
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Astellas Pharma
Vertical(s)
Life Sciences
Corporate Office
  • 1030 Massachusetts Avenue
  • Suite 200
  • Cambridge, MA 02138
  • United States
+1 (617)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mitobridge Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-Jan-2018 $225M Completed Generating Revenue
3. Accelerator/Incubator Completed Startup
2. Early Stage VC (Series A) 04-Feb-2014 $45M $45M Completed Startup
1. Seed Round 01-Jan-2011 Completed Startup
To view Mitobridge’s complete valuation and funding history, request access »

Mitobridge Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
Series A1
Series AS 15,000,000 $0.000100 $0.08 $1 $1 1x $1 17.65%
To view Mitobridge’s complete cap table history, request access »

Mitobridge Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule therapeutics designed to enhance mitochondrial function. The company's small molecule therap
Drug Discovery
Cambridge, MA
26 As of 2023

Durham, NC
 

Lyon, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mitobridge Competitors (70)

One of Mitobridge’s 70 competitors is Atox Bio, a Venture Capital-Backed company based in Durham, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Atox Bio Venture Capital-Backed Durham, NC
PHAXIAM Therapeutics Formerly VC-backed Lyon, France
Allorion Therapeutics Venture Capital-Backed Natick, MA
Visterra Formerly VC-backed Waltham, MA
Aurora Biopharma Angel-Backed Cambridge, MA
You’re viewing 5 of 70 competitors. Get the full list »

Mitobridge Patents

  • 48

    Total Documents Applications and Grants

  • Total Patents Families

  • 31

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

Mitobridge Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3221429-A1 Methods of use of ppar agonist compounds and pharmaceutical compositions thereof Pending 02-Jun-2021
AU-2022286415-A1 Methods of use of ppar agonist compounds and pharmaceutical compositions thereof Pending 02-Jun-2021
AU-2021251753-A1 Cd38 inhibitors Pending 07-Apr-2020
CA-3179589-A1 Cd38 inhibitors Pending 07-Apr-2020
CA-3135615-A1 Hmox1 inducers Pending 12-Apr-2019 C07D413/12
To view Mitobridge’s complete patent history, request access »

Mitobridge Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mitobridge Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Astellas Venture Management Corporate Venture Capital Minority
Ecole Polytechnique Federale de Lausanne University Minority
Longwood Fund Venture Capital Minority
MPM BioImpact Venture Capital Minority
To view Mitobridge’s complete investors history, request access »

Ready to get started?

Request a free trial

Mitobridge FAQs

  • When was Mitobridge founded?

    Mitobridge was founded in 2011.

  • Where is Mitobridge headquartered?

    Mitobridge is headquartered in Cambridge, MA.

  • What is the size of Mitobridge?

    Mitobridge has 26 total employees.

  • What industry is Mitobridge in?

    Mitobridge’s primary industry is Drug Discovery.

  • Is Mitobridge a private or public company?

    Mitobridge is a Private company.

  • What is the current valuation of Mitobridge?

    The current valuation of Mitobridge is .

  • What is Mitobridge’s current revenue?

    The current revenue for Mitobridge is .

  • How much funding has Mitobridge raised over time?

    Mitobridge has raised $45M.

  • Who are Mitobridge’s investors?

    Astellas Venture Management, Ecole Polytechnique Federale de Lausanne, Longwood Fund, and MPM BioImpact have invested in Mitobridge.

  • Who are Mitobridge’s competitors?

    Atox Bio, PHAXIAM Therapeutics, Allorion Therapeutics, Visterra, and Aurora Biopharma are some of the 70 competitors of Mitobridge.

  • When was Mitobridge acquired?

    Mitobridge was acquired on 23-Jan-2018.

  • Who acquired Mitobridge?

    Mitobridge was acquired by Astellas Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »